Pharmaceutical News

RSS

Performance Plus Marketing wins IMA's Circle of Excellence Award for Victoza campaign

In today's troubled economy, keeping a sales force motivated to perform can be critical to the success of a business. That's why Novo Nordisk turned to Performance Plus Marketing (PPM) of Roswell, GA, to build an incentive program to support the launch of its Diabetes medication, Victoza(R). The campaign's unprecedented success resulted in the Incentive Marketing Association's Circle of Excellence Award for Best Sales Incentive Program.

9 Sep 2010

BioMedTracker launches Thought Leader Opinions service for drug information

BioMedTracker, a product of Sagient Research Systems, the leading provider of competitive intelligence and investment analytics on the biotech/pharmaceutical sector, today announced the recent launch of its new service, Thought Leader Opinions (TLO). This service provides its subscribers with direct access to the latest expert opinions in the disease areas that they follow within the intuitive BioMedTracker drug information platform.

9 Sep 2010

Questcor Pharmaceuticals provides update on sNDA for H.P. Acthar Gel

Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.

9 Sep 2010

SDI's VaccineTrack data reports on season's flu vaccination

More than 690,000 Americans have already received this season's flu vaccine from their doctor, according to SDI's VaccineTrack data through Sept. 4. VaccineTrack provides syndicated weekly vaccine usage by physicians based on medical office electronic healthcare reimbursement claims data.

9 Sep 2010

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

A federal appeals court on Tuesday said it will not revisit its decision to uphold settlements that allow pharmaceutical companies to pay competitors to keep generic versions of their drugs off the market, The Wall Street Journal reports. "In April, the U.S. Second Circuit Court of Appeals [in New York] affirmed the legality of a settlement in which Bayer AG, in essence, paid Barr Pharmaceuticals Inc., a potential generic competitor, to drop its patent challenge to Cipro, a Bayer antibiotic."

9 Sep 2010

C.A.R.E.S. Alliance launches online tools for addressing misuse and abuse of pain medications

The C.A.R.E.S. Alliance, a new patient safety organization, today launched a range of online tools designed to help solve the growing problem of misuse and abuse of opioids by identifying the risks associated with these powerful pain medications. The free resources offered through the C.A.R.E.S. (Collaborating & Acting Responsibly to Ensure Safety) Alliance promote safety in prescribing, dispensing, using, storing and disposing of these commonly abused pain medications.

9 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Quick-Med expands and strengthens NIMBUS technology intellectual property

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

8 Sep 2010

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.

8 Sep 2010

Experts gathered for UNAIDS, WHO meeting recommend follow-up studies of ARV-containing microbicide gel start soon

Experts gathered at a joint meeting of UNAIDS and the WHO last week called for two additional clinical trials to test the effectiveness and safety of a microbicide vaginal gel containing the antiretroviral tenofovir, which previous studies have shown reduces the risk of HIV transmission in women who used it before and after sex by 39 percent, PANA/Afrique en ligne reports (9/5).

8 Sep 2010

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel.

8 Sep 2010

La Jolla Pharmaceutical seeks clinical product for lupus treatment

La Jolla Pharmaceutical Company provided an update today that the Company is actively seeking and evaluating potential pharmaceutical products for in-licensing or acquisition and has engaged consultants to determine whether there is any potential for the further development of Riquent for the treatment of lupus.

8 Sep 2010

Global Fund investigates allegations that donated malaria drugs were stolen, resold in some African countries

After recent research found that some donated malaria drugs are being stolen and sold commercially in several African countries, the Global Fund to Fight AIDS, Tuberculosis and Malaria Communications Director Joe Liden said the group is looking into the situation "in a number of countries," PBS' NewsHour's blog, "The Rundown" reports.

8 Sep 2010

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Forest Laboratories, Inc. announced that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil for the treatment of community acquired bacterial pneumonia (CABP) and voted 18 - 0 in favor of approval for complicated skin and skin structure infections (cSSSI).

8 Sep 2010

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA.

8 Sep 2010

Pharmaceutical News

Performance Plus Marketing wins IMA's Circle of Excellence Award for Victoza campaign

BioMedTracker launches Thought Leader Opinions service for drug information

Questcor Pharmaceuticals provides update on sNDA for H.P. Acthar Gel

SDI's VaccineTrack data reports on season's flu vaccination

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

C.A.R.E.S. Alliance launches online tools for addressing misuse and abuse of pain medications

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Zyngenia completes $15M Series A financing extension from NEA

Quick-Med expands and strengthens NIMBUS technology intellectual property

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

Experts gathered for UNAIDS, WHO meeting recommend follow-up studies of ARV-containing microbicide gel start soon

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

La Jolla Pharmaceutical seeks clinical product for lupus treatment

Global Fund investigates allegations that donated malaria drugs were stolen, resold in some African countries

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News